Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma.

Leukemia & lymphoma - 1 Dec 2022

Nolan James, Murphy Catherine, Dinneen Kate, Lee Greg, Higgins Elizabeth, Bacon Larry, O'Brien David, Flavin Richard, Quinn Fiona, Vandenberghe Elisabeth

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to High-Throughput Nucleotide Sequencing
Share to Immunohistochemistry
Share to Lymphoma, Mantle-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Risk Assessment

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 36059262
DOI: 10.1080/10428194.2022.2118529

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma.PMID 36059262Read ↗

Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma.Semantic proximity Read ↗

p53 is associated with high‐risk and pinpointsTP53missense mutations in mantle cell lymphomaSemantic proximity Read ↗

TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.Semantic proximity Read ↗

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.Semantic proximity Read ↗

Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.Semantic proximity Read ↗

ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patientsSemantic proximity Read ↗

Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas.Semantic proximity Read ↗

Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP 53 alterationsSemantic proximity Read ↗

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront TherapySemantic proximity Read ↗

Biological and clinical determinants shaping heterogeneity in mantle cell lymphomaSemantic proximity Read ↗

Genomic landscape and prognostic analysis of mantle cell lymphoma.Semantic proximity Read ↗

TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.